What a Lyme Western blot measures, and where it belongs
The result is useful only with the first Lyme test, possible tick exposure, symptoms, and timing.
Second tier
It follows a reactive first immunoassay
The blot looks for two classes of antibodies binding to selected Borrelia proteins after a positive or equivocal first test in the standard US algorithm.
Not one band
Use the complete IgM or IgG interpretation
Validated rules count a defined group of bands. One reactive line, including p41, is not a separate Lyme diagnosis.
Not always a Western blot
Modified testing uses two immunoassays
Some FDA-cleared algorithms use another EIA as the second tier and produce no band report.
Antibodies do not show current activity
Antibodies can outlast infection
A positive IgG result can reflect recent or remote infection and cannot show that treatment failed or bacteria remain active.
Interpretation needs the first-tier result, exact method, IgM or IgG results, symptom duration, exposure, prior Lyme history, objective findings, and accredited criteria. Missing any of those can turn a real laboratory line into the wrong clinical conclusion.
Save this test
Save the sequence, not just the bands
Keep the exposure, symptom timing, both tests, full antibody results, past Lyme history, and next step together.
Repeat only if the first sample was too early, the result was invalid, or the clinician names another clear reason.
How do age, sex, pregnancy, immune response, and past Lyme affect the result?
The lab uses the same band rules for males and females. Age, pregnancy, past infection, immune health, exposure place, symptoms, and timing affect how the result is used.
Children and teenagers
Use a pediatric clinical assessment with the same complete two-tier principle, not an adult symptom checklist or one band. Mayo lists its immunoblot reference as negative for all ages. Li 2025 found similar positive counts between modified and standard algorithms in people under 18, but that retrospective laboratory comparison did not validate home interpretation.
Adult women and men
There are no sex-specific IgM or IgG band criteria. Exposure, objective findings, duration, prior infection, autoimmune disease, and cross-reacting infections matter more than sex when interpreting the algorithm.
Pregnancy and breastfeeding
Pregnancy does not create a different positive-band rule. A possible expanding rash or objective Lyme manifestation still needs timely clinical review because treatment choices and medicine risks require pregnancy-specific discussion. Seek care without waiting for home-read band reports.
Older adults and altered immune response
Past antibodies, autoimmune disease, other infections, earlier Lyme disease, and rare antibody problems can make the result harder to read. A negative IgG after months or years of untreated symptoms usually makes Lyme disease much less likely. Lab error and rare antibody deficiency are exceptions.
Previously treated or possible reinfection
IgG may stay positive for years after treatment. For new symptoms after a new exposure, the prior report, objective findings, and alternative diagnoses matter because another blot may not distinguish old antibodies from reinfection.
How to prepare for Lyme antibody testing
Write down where and when a possible tick exposure happened. Add when each symptom began, whether a rash grew, and when antibiotics started. IgM is only used during the first 30 days of symptoms.
Confirm the laboratory's complete algorithm. Standard US two-tier testing adds both antibody immunoblots after a positive or borderline (equivocal) first EIA or IFA test. A negative first tier usually stops the algorithm. In an FDA-cleared EIA-to-EIA pathway, the second test is another immunoassay, not a Western blot.
Lyme antibody testing itself usually needs no fasting or set time of day. Follow the written plan for the complete order. Current Mayo and Labcorp immunoblot methods use serum, and the same blood sample can usually complete both tiers.
A typical expanding erythema migrans rash after plausible exposure is diagnosed clinically in current US guidance. Seek care without waiting for an early antibody result. Early serology can be negative because antibodies take time to develop.
Bring prior Lyme reports and treatment dates. Antibodies can remain detectable for months to years, so an old positive result can affect a new report and cannot establish active infection or cure.
Keep the first test and both overall antibody results. Also save each band if shown, the test maker, FDA status, draw date, and number of days with symptoms.
Name both tiers
Save the first immunoassay and the second-tier method. Call an immunoblot the second tier, not a standalone test.
Count days, not bands alone
Record the exact symptom-onset date. IgM immunoblot interpretation is limited to the first 30 days.
Read the overall result
Use the laboratory's validated overall interpretations, not one reactive band or an internet band chart.
Keep past infection visible
Add earlier Lyme results, treatment, later tick exposures, and objective new findings.
Choose the clinical pathway
Use rash, neurological, cardiac, joint, or other objective findings to decide which checks you need next.
How to understand Lyme IgM and IgG immunoblot results
Read the report in order: first tier, symptom duration, IgM overall result, IgG overall result, assay and criteria, then exposure and objective findings. Leave individual bands for later.
Two-tier result not confirmed
Complete two-tier result negative or not confirmed
The validated algorithm didn't confirm any laboratory evidence. This is more useful when testing occurred at an appropriate time. A result collected very early may be negative before antibodies develop, and a typical erythema migrans rash is a clinical diagnosis.
IgM positive within the early window
IgM immunoblot positive within 30 days of symptom onset, with a reactive first tier
At least 2 of the 3 specified IgM bands met the validated rule and may support recent infection in the right clinical setting. After 30 days, an IgM-only result should not be used as evidence of active Lyme disease.
IgG positive
IgG immunoblot positive, with a reactive first tier
At least 5 of the 10 named IgG bands met the rule. This supports an infection in the recent or distant past. The result does not show whether the infection is active now.
Invalid, discordant, or nonstandard report
Invalid, inconclusive, discordant, missing first tier, or interpreted with a different band rule
Treat the report as neither positive nor negative. Confirm the assay, algorithm, symptom duration, FDA status, and report criteria. An invalid specimen may need a new sample; a nonstandard interpretation may need review through an accredited laboratory.
Positive antibodies do not prove active infection
IgM can be misleading after 30 days, IgG can persist for years, and early infection can still be antibody-negative. The test supports a clinical diagnosis only when timing, exposure, objective findings, and the validated algorithm agree.
See research details
Interpret band criteria, early-test sensitivity, past antibodies, EIA-to-EIA pathways, country guidance, and neurological testing separately rather than merging them into one conclusion.
Read the overall validated IgM or IgG interpretation after a reactive first tier. You can't diagnose Lyme disease from one band. Use only the testing laboratory's band criteria.
Put symptom onset beside the result. A late IgM-only result can't show that years of fatigue, pain, or cognitive symptoms are active Lyme disease.
The cited sensitivity figures apply to early Lyme disease, not to every stage. A typical erythema migrans rash is assessed clinically, and later objective manifestations have different pretest probability and test performance.
Before searching for bands, check whether the laboratory used standard or modified two-tier testing. A valid modified result can have no band report at all.
Use new objective findings, exposure, timing, and alternative diagnoses. Skip repeat blots meant to make bands disappear. Lasting bands don't prove bacteria remain active.
A changed laboratory, manufacturer, or algorithm can change classification. Keep the method with every result. A changed result doesn't prove worsening or recovery.
A serum Western blot alone does not diagnose meningitis or central nervous system infection. New facial weakness, severe headache with neck stiffness, weakness, fainting, chest pain, palpitations, or shortness of breath needs prompt clinical assessment.
Use the accredited pathway for the country and place of exposure. Judge each country's report by that country's own organism panel, band rule, and repeat interval.
What to do while the result is reviewed
Food and supplements cannot safely change a Lyme antibody band. Keep a clear exposure and symptom timeline, prevent new tick bites, and save the full report.
Make one exposure and symptom timeline
Record travel, outdoor locations, the tick date if known, how long it may have been attached, and any rash. Add fever, facial weakness, headache, heart symptoms, fainting, joint swelling, numbness, pain, tiredness, and thinking problems. Include antibiotic and blood-draw dates.
Photograph an expanding rash and seek care
Take a clear dated photo with a ruler or familiar object for size. Seek care for a typical growing rash after possible exposure. Early blood tests can still be negative.
Keep the full report, not a band screenshot
Save the first-tier assay, overall two-tier interpretation, IgM and IgG results, symptom duration, manufacturer, FDA status, and every reported band. A cropped image of one reactive band removes the information needed to interpret it.
Reduce the next exposure
Use repellent and protective clothing when needed. Check skin and gear after time in tick areas, shower, and remove attached ticks quickly with fine-tipped tweezers.
Keep other causes in the workup
If tiredness, pain, or thinking problems continue, keep other causes in the workup. Review sleep, medicines, anemia, thyroid, mood, infection, and nervous-system findings instead of relying on an old band.
Do not self-start leftover antibiotics, prolonged antibiotics, antimicrobial herbs, binders, detox products, or a restrictive diet from one band or one positive antibody report. Seek urgent care for new facial weakness, severe headache with neck stiffness, fainting, chest pain, palpitations, shortness of breath, new weakness, or rapidly worsening illness.
What to save with a Lyme Western blot result
Keep these together
- Exposure location and date, tick details, rash photos, symptom-onset date, and objective findings
- First-tier assay, value or interpretation, and whether the laboratory used standard or modified two-tier testing
- Second-tier method, manufacturer, FDA status, IgM and IgG overall interpretations, every reported band, and report criteria
- Specimen, collection date, antibiotics before testing, prior Lyme results, prior treatment, later exposures, and immune conditions
- Clinician interpretation, rash, neurological, cardiac or joint pathway, alternative diagnoses, repeat conditions, and next decision
Question for the visit
“Does this complete two-tier result fit the exposure, symptom timing, and objective findings, and what would distinguish past antibodies, early testing, a false-positive pattern, reinfection, or another cause?”
Sources for Lyme Disease Immunoblot (Western Blot)
Current US two-tier sequence, early window, cross-reactions, 30-day IgM rule, and treatment-monitoring limit.
Exact IgM and IgG band criteria, result combinations, repeat window, cross-reactive p41 limit, and reporting language.
FDA-cleared EIA-to-EIA pathway and its distinction from Western blot confirmation.
US acceptance of FDA-cleared modified two-tier algorithms.
Clinical diagnosis of typical erythema migrans, two-tier testing, prior antibodies, neurological antibody index, and persistent-symptom boundaries.
Current serum method, all-age reference, band-count criteria, invalid result, specimen, cross-reactions, and no-screening limit.
Current second-tier line-blot method, serum requirements, use, and standalone-sensitivity limit.
Four FDA-cleared algorithms in 107 early-Lyme cases and 144 endemic controls, with sensitivity, specificity, discordance, and conflict disclosures.
Matched real-world standard versus modified testing in 133,416 people, age-stratified positivity, and Quest employment disclosure.
Commercial modified-algorithm assay agreement and 95-sample overall concordance.
Laboratory-diagnosis review, assay distinctions, early limits, and persistent antibodies.
Published IDSA, AAN, and ACR guideline record.
Current UK screening and ViraChip confirmation, repeat timing, accredited testing, and paired CSF-serum pathway.
UK testing sequence, selected immunoblot after negative ELISA, specialist review, and accredited-laboratory rules.
Travel context, accredited two-tier testing, and rule against immunoblot without a reactive screen.
See each claim's sources
procedure
In US standard two-tier testing, a positive or equivocal first immunoassay is followed by an IgM and IgG immunoblot; both steps are required.range
Recommended US immunoblot criteria use at least 2 of 3 specified IgM bands or at least 5 of 10 specified IgG bands.limitation
IgM immunoblot results should be disregarded when symptoms have lasted more than 30 days.limitation
Two-tier antibody testing can be negative early in infection, and a typical erythema migrans rash is diagnosed clinically rather than by waiting for serology.limitation
Lyme antibodies may remain detectable for months to years and should not be used to determine cure or monitor treatment response.procedure
FDA-cleared modified two-tier Lyme algorithms use a second immunoassay instead of a Western blot.limitation
In 107 early-Lyme cases and 144 endemic controls, four FDA-cleared algorithms had initial sensitivity of 22 to 36 percent and specificity of 98 to 100 percent, with discordance across algorithms.limitation
A 2025 matched national-laboratory analysis of 66,708 people per group found different positivity between modified and standard algorithms in adults, with similar positivity in people under 18.procedure
When CSF testing is used for suspected central nervous system Lyme neuroborreliosis, simultaneous CSF and serum should be used for a validated antibody index.limitation
US, UK, and Australian Lyme testing pathways differ, so country, exposure location, assay, and accredited interpretation must remain attached.